Mineralys Therapeutics is developing targeted therapies for hypertension and related cardio-renal-metabolic diseases driven by dysregulated aldosterone. Their approach focuses on improving patient outcomes by addressing the underlying mechanisms of aldosterone's role in these conditions.
Funding
$120M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
TCFounders
Product
Problem
Hypertension, chronic kidney disease (CKD), and related cardio-renal-metabolic diseases are often driven by dysregulated aldosterone, a hormone that regulates sodium and potassium levels in the body. Current treatments do not always effectively target the underlying mechanisms of aldosterone's role in these conditions, leading to suboptimal patient outcomes.
Solution
Mineralys Therapeutics is developing targeted therapies to address hypertension, CKD, and related cardio-renal-metabolic diseases driven by dysregulated aldosterone. Their lead product, Lorundrostat, is designed to selectively block aldosterone synthase, the enzyme responsible for aldosterone production, aiming to normalize aldosterone levels and improve patient outcomes. By specifically targeting aldosterone synthase, Lorundrostat seeks to provide a more precise and effective approach to managing these conditions compared to existing treatments. This targeted approach has the potential to reduce the risk of off-target effects and improve the overall safety profile for patients. The company is focused on advancing Lorundrostat through clinical development to address the unmet needs of individuals with hypertension and related diseases.
Target Audience
The primary target audience includes individuals with hypertension, chronic kidney disease, and related cardio-renal-metabolic diseases where dysregulated aldosterone plays a significant role, as well as the physicians who treat them.
Features
- Lorundrostat: A selective aldosterone synthase inhibitor in development.
- Targeted approach: Focuses on the underlying mechanisms of aldosterone dysregulation.
- Potential for improved outcomes in hypertension, CKD, and cardio-renal-metabolic diseases.